MetaVia Inc. (Nasdaq: MTVA) announced on October 13, 2026, that it has appointed Dr. Sarah Kaplan Browne as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings over 20 years of experience in clinical development, regulatory science, and clinical medicine, with a specific focus on liver and metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH).
In her previous role as Vice President of Clinical Development at Altimmune, Inc., Dr. Browne led clinical development programs in obesity, metabolic, and liver diseases. She was responsible for advancing the dual GLP-1/glucagon receptor agonist pemvidutide from first-in-human studies through Phase 2 and establishing a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Prior to Altimmune, she served as a Senior Advisor for Clinical Review at the FDA’s Center for Biologics Evaluation and Research (CBER) and held positions at the National Institutes of Health (NIH) and the Veterans Affairs Medical Center.
MetaVia’s President and Chief Executive Officer, Hyung Heon Kim, stated that Dr. Browne’s expertise in leading the clinical development of pemvidutide and her experience with dual GLP-1/glucagon receptor agonists will be valuable as the company prepares for the upcoming fourth quarter 2026 topline data readout from Part 3 of its Phase 1 clinical trial of DA-1726. The company is also developing vanoglipel (DA-1241) for the treatment of MASH.
Dr. Browne holds a B.A. from Williams College and an M.D. from Virginia Commonwealth University. She completed her residency in internal medicine at Brigham and Women's Hospital and Harvard Medical School, followed by a fellowship in infectious diseases at the NIH. She is board certified in internal medicine and infectious diseases.
